Filing Flows › Comparisons › SUPN vs COLL
Supernus Pharmaceuticals vs Collegium Pharmaceutical: SUPN and COLL compared
Supernus Pharmaceuticals is the larger company: $227M of revenue in its latest quarter (Q3 2026) against $216M for Collegium Pharmaceutical (Q3 2026). Supernus Pharmaceuticals is growing faster (+18% against +3% a year earlier). Collegium Pharmaceutical is more profitable, with an operating margin of 13.3% against 9.3%.
Where the money goes: SUPN and COLL
Supernus Pharmaceuticals (SUPN) · Q3 2026
Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%, net earnings $20.9M, operating cash flow $6.6M. The chart follows the revenue to costs, profit and cash.
Collegium Pharmaceutical (COLL) · Q3 2026
Collegium Pharmaceutical, Q3 2026: revenue $216M (+3% year over year), operating margin 13.3%, net earnings $21.8M, operating cash flow $86.5M. The chart follows the revenue to costs, profit and cash.
| Supernus Pharmaceuticals (SUPN) | Collegium Pharmaceutical (COLL) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $227M | $216M |
| Revenue growth, Y/Y | +18% | +3% |
| Gross margin | — | 58.0% |
| Operating margin | 9.3% | 13.3% |
| Net earnings | $20.9M | $21.8M |
| Net margin | 9.2% | 10.1% |
| Operating cash flow | $6.6M | $86.5M |
| Free cash flow | $6.4M | $86.3M |
| Market value | — | $717M |
| P/E | — | 15.0× |
| Analysts’ mean target | — | $49.00 |
Where the revenue comes from
Supernus Pharmaceuticals
- Net product sales: $179M (79%)
- ONAPGO: $17.1M (8%)
- Trokendi XR: $10.2M (5%)
- Oxtellar XR: $8.0M (4%)
Collegium Pharmaceutical
- Belbuca: $57.7M (27%)
- Jornay PM: $51.9M (24%)
- Xtampza ER: $45.8M (21%)
- Azstarys: $26.5M (12%)
Questions
Which is bigger, Supernus Pharmaceuticals or Collegium Pharmaceutical?
Supernus Pharmaceuticals is the larger company: $227M of revenue in its latest quarter (Q3 2026) against $216M for Collegium Pharmaceutical (Q3 2026).
Is Supernus Pharmaceuticals or Collegium Pharmaceutical growing faster?
Supernus Pharmaceuticals is growing faster (+18% against +3% a year earlier).
Which is more profitable, Supernus Pharmaceuticals or Collegium Pharmaceutical?
Collegium Pharmaceutical is more profitable, with an operating margin of 13.3% against 9.3%.
More: Supernus Pharmaceuticals earnings · how Supernus Pharmaceuticals makes money · Collegium Pharmaceutical earnings · how Collegium Pharmaceutical makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 29, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.